Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tristel's gross profit for the
six
months ended in Dec. 2025 was $27.81 Mil. Tristel's gross profit for the trailing twelve months (TTM) ended in Dec. 2025 was $53.57 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Tristel's gross profit for the
six
months ended in Dec. 2025 was $27.81 Mil. Tristel's Revenue for the
six
months ended in Dec. 2025 was $34.34 Mil. Therefore, Tristel's Gross Margin % for the quarter that ended in Dec. 2025 was 81.00%.
Tristel had a gross margin of 81.00% for the quarter that ended in Dec. 2025 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Tristel was 80.62%. The lowest was 73.40%. And the median was 79.34%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Tristel had a gross margin of 81.00% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Tristel Gross Profit Related Terms
Tristel Gross Profit Historical Data
* Premium members only.
The historical data trend for Tristel's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Tristel's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tristel Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tristel's Gross Profit distribution charts can be found below:
* The bar in red indicates where Tristel's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $53.57 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Tristel (TSNLF) has a Gross Profit of $53.57 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Tristel and its competitors.
Is Tristel's Gross Profit too high?
Tristel's current Gross Profit is $53.57 Mil. Overall, Tristel has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tristel's Gross Profit compare to ISRG and BDX?
Tristel's Gross Profit of $53.57 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Tristel and its competitors. Tristel's current Gross Profit is $53.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tristel stock overvalued right now?
Based on GuruFocus' analysis, Tristel (TSNLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.00, compared to a current price of $5.74 — trading 18% below its estimated fair value. The current Gross Profit is $53.57 Mil. Tristel's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Tristel (TSNLF), the current Gross Profit is $53.57 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tristel (TSNLF) Overvalued in 2026?
Based on GuruFocus' analysis, Tristel stock appears to be undervalued.
The current stock price of $5.74 is trading 18% below its estimated GF Value™ of $7.00.
GuruFocus considers Tristel to be Modestly Undervalued.
Key valuation signals for TSNLF:
Gross Profit: $53.57 Mil
GF Value™: $7.00 vs. price of $5.74 (18% below fair value)
No single metric tells the full story. See the TSNLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tristel PLC's business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand and for the sporicidal disinfection of environmental surfaces under the Cache brand. Its operating segments include hospital medical device decontamination products used predominantly for infection control in hospitals; the manufacture and sale of hospital environmental surface disinfection products; and pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare. The company generates the majority of its revenue from hospital medical device decontamination and operates geographically in the UK and overseas markets.
95GF Score
Get the complete analysis for TSNLF
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNLF has been successfully added to your 
